Clinical Research Papers:

Can we consider discontinuation of hypomethylating agents in patients with myelodysplastic syndrome : a retrospective study from The Korean Society of Hematology AML/MDS Working Party

Da Jung Kim, Ho Sup Lee _, Joon-Ho Moon, Sang Kyun Sohn, Hyeoung Joon Kim, June-Won Cheong, Deog-Yeon Jo, Hawk Kim, Hyewon Lee, Soo-Mee Bang, Won Sik Lee, Yong Park, Mark Hong Lee, Jae Hoon Lee, Sung Hwa Bae, Min Kyoung Kim and The Korean Society of Hematology AML/MDS Working Party

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:79414-79424. https://doi.org/10.18632/oncotarget.18258

Metrics: PDF 1574 views  |   HTML 2364 views  |   ?  


Da Jung Kim1, Ho Sup Lee1, Joon-Ho Moon2, Sang Kyun Sohn2, Hyeoung Joon Kim3, June-Won Cheong4, Deog-Yeon Jo5, Hawk Kim6, Hyewon Lee7, Soo-Mee Bang8, Won Sik Lee9, Yong Park10, Mark Hong Lee11, Jae Hoon Lee12, Sung Hwa Bae13, Min Kyoung Kim14 and The Korean Society of Hematology AML/MDS Working Party

1Department of Internal Medicine, Kosin University College of Medicine, Kosin University Gospel Hospital, Busan, South Korea

2Department of Hematology/Oncology, Kyungpook National University Hospital, Daegu, South Korea

3Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Jeollanamdo, South Korea

4Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea

5Department of Internal Medicine, Chungnam National University Hospital, Chungnam National University, Daejeon, South Korea

6Division of Hematology and Cellular Therapy, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea

7Department of Hematology-Oncology, Center for Hematologic Malignancy, National Cancer Center, Goyang, South Korea

8Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul, South Korea

9Department of Internal Medicine, Busan Paik Hospital, Busan, South Korea

10Department of Internal Medicine, Korea University College of Medicine, Seoul, South Korea

11Division of Hematology-Oncology, Department of Internal Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, South Korea

12Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, South Korea

13Department of Internal Medicine, Daegu Catholic University Medical Center, Daegu, South Korea

14Department of Hematology-Oncology, Yeungnam University Medical Center, Yeungnam University School of Medicine, Daegu, South Korea

Correspondence to:

Ho Sup Lee, email: [email protected]

Keywords: myelodysplastic syndrome, discontinuation, survival, decitabine, azacitidine

Received: March 17, 2017     Accepted: April 28, 2017     Published: May 29, 2017


It is often difficult to continue treatment with hypomethylating agent(HMA) in clinical practice because of problems such as toxicities, poor economics, etc. We compared clinical outcomes of those patients who continued HMA and those who discontinued HMA because of other causes, and evaluated factors associated with survival in those patients who discontinued HMA.

Patients were divided into two groups: treatment failure, those who stopped treatment due to disease progression; and discontinuation, those who discontinued treatment because of other causes.

The median progression free survival(PFS) was 9.2 months (range 7.7 – 10.7 months) vs 28.9 months (range 22.6 – 35.2) in the treatment failure and discontinuation groups, respectively (P < 0.001). In a multivariate analysis, a lower risk by WPSS was an independent predictive factor for a longer PFS, and a lower risk by WPSS and median number of HMA cycles greater than seven were independent predictive factors for longer overall survival(OS) only in the discontinuation group.

Patients who discontinued HMA without disease progression showed a prolonged survival than those who failed HMA treatment. Especially, a lower risk by WPSS and longer duration of HMA treatment may be predictive factors for a longer PFS and OS in patients who discontinued HMA.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18258